Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 993-1001

  Wong, Blenda Chi Kwan ^a   Zhang, Hongqi ^a   Qin, Ling ^b   Chen, Hubiao ^a   Fang, Chen ^a   Lu, Aiping ^a   Yang, Zhijun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer chemotherapy; Cell surface antigen; Conjugation; Hypoxia; Liposome; Nanotechnology

Indexed keywords

CARBONATE DEHYDRATASE IX; DOCETAXEL; IMMUNOLIPOSOME; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; DRUG CARRIER; LIPOSOME; TAXOID; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG UPTAKE; ENCAPSULATION; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PARTICLE SIZE; PROTEIN EXPRESSION; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COMPARATIVE STUDY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FLOW CYTOMETRY; HUMANS; LIPOSOMES; LUNG NEOPLASMS; PARTICLE SIZE; TAXOIDS;

EID: 84904978899     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S63235     Document Type: Article

References (43)

1. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des.2008; 14(7): 685-698.
2. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res.1997; 57(14): 2827-2831.
3. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol.1998; 153(1): 279-285.
4. Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol.2001; 158(3): 1011-1019.
5. Vermylen P, Roufosse C, Burny A, et al. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J.1999; 14(4): 806-811.
6. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res.2001; 61(17): 6394-6399.
7. Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2010; 102(11): 1627-1635.
8. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol.2001; 19(16): 3660-3668.
9. Måseide K, Kandel RA, Bell RS, et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res. 2004; 10(13): 4464-4471.
10. Haapasalo JA, Nordfors KM, Hilvo M, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res.2006; 12(2): 473-477.
11. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res.2006; 12(5): 1507-1514.
12. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003; 21(3): 473-482.
13. Pastoreková S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997; 112(2): 398-408.
14. Kivelä AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol.2000; 114(3): 197-204.
15. Karhumaa P, Kaunisto K, Parkkila S, et al. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol Hum Reprod.2001; 7(7): 611-616.
16. Surfus JE, Hank JA, Oosterwijk E, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol.1996; 19(3): 184-191.
17. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferonalpha-2a in metastatic renal cell carcinoma patients. World J Urol. 2011; 29(1): 121-126.
18. Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010; 16(29): 3255-3263.
19. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov.2005; 4(2): 145-160.
20. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther.2006; 8(1): 39-45.
21. Shinkai M, Le B, Honda H, et al. Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J Cancer Res.2001; 92(10): 1138-1145.
22. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60(24): 7075-7083.
23. Pons M, Foradada M, Estelrich J. Liposomes obtained by the ethanol injection method. Int J Pharm.1993; 95(1-3): 51-56.
24. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta.2001; 1513(2): 207-216.
25. Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release.2011; 150(1): 2-22.
26. Závada J, Závadová Z, Zat'ovicová M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer.2003; 89(6): 1067-1071.
27. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des.2004; 10(24): 2981-2989.
28. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18): 812-818.
29. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release.2010; 148(2): 135-146.
30. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol.2007; 25(10): 1165-1170.
31. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine.2006; 1(3): 297-315.
32. Sheehan JP, Sheehan JM, Holmberg EG, Geisert EE, Helm GA. A horseradish peroxidase-light and electron microscopic study of immunoliposomes utilized for intracellular delivery to the rat striatum. Neurosci Lett.2002; 333(3): 212-216.
33. Mellor HR, Callaghan R. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemother Pharmacol.2011; 68(5): 1179-1190.
34. Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol.2011; 701: 115-122.
35. Xiao-Dong L, Zhi-Hong Y, Hui-Wen Y. Repetitive/temporal hypoxia increased P-glycoprotein expression in cultured rat brain microvascular endothelial cells in vitro. Neurosci Lett.2008; 432(3): 184-187.
36. Xia S, Yu S, Yuan X. Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line. J Huazhong Univ Sci Technolog Med Sci.2005; 25(3): 279-281.
37. Omelyanenko V, Kopecková P, Gentry C, Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release.1998; 53(1-3): 25-37.
38. Shen F, Chu S, Bence AK, et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther.2008; 324(1): 95-102.
39. Baas P, Belderbos JS, van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol.2011; 23(2): 140-149.
40. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res.2003; 9(15): 5532-5539.
41. Gagnadoux F, Pape AL, Lemarié E, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005; 26(4): 657-661.
42. Mercadal M, Domingo JC, Petriz J, Garcia J, de Madariaga MA. Preparation of immunoliposomes bearing poly(ethylene glycol)-coupled monoclonal antibody linked via a cleavable disulfide bond for ex vivo applications. Biochim Biophys Acta.2000; 1509(1-2): 299-310.
43. Mercadal M, Domingo JC, Petriz J, Garcia J, de Madariaga MA. A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains. Biochim Biophys Acta. 1999; 1418(1): 232-238.